Market Update (NYSE:CVS): CVS Health CEO Larry Merlo Keynotes at 2016 AHIP Institute and Expo

[PR Newswire] – WOONSOCKET, R.I., June 16, 2016 /PRNewswire/ — CVS Health (CVS) President and Chief Executive Officer Larry Merlo and Chief Medical Officer Troyen A. Brennan, M.D., will deliver remarks about the major public health challenges facing our country at this week’s annual America’s Health Insurance Plans (AHIP) Institute and Expo in Las Vegas, Nevada. CVS Health’s executives will discuss how innovation can create new models of patient care and delivery to address rising rates of chronic diseases while lowering health care costs for both payers and patients. “Between now and 2030, the cumulative cost of chronic illness is projected to grow to $42 trillion and, despite all efforts to encourage Americans to live healthier lifestyles, we don’t seem to be gaining ground,” Merlo says. Read more on this. CVS Health Corporation (CVS) , with a current market cap of $102.34B, opened at $95.40. Looking at today’s trading action, the company’s one day range from $94.57 to $95.80 with a one year range of $81.37 to $113.65. CVS shares are currently priced at 16.47x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 10.44x forward p/e ratio. The company pays shareholders $1.70 per share in dividend income per year, for a current yield of 1.76%. According to a consensus of 24 analysts, the earnings estimate of $1.30 per share would be $0.08 better than the year-ago quarter and a $0.05 sequential decrease. The full-year EPS estimate is $5.83 which would be a $0.67 better than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $44.30 Billion. If realized, that would be a 19.18% increase over the year-ago quarter. More recently, Atlantic Equities Initiated CVS at Overweight (Feb 3, 2016). Previously, Robert W. Baird Initiated CVS at to Outperform. When considering if the stock is under or overvalued, the average price target is $114.24, which is 19.75% above where the stock opened this morning. See more in (NYSE:CVS) Similar Articles: Market Update (NYSE:CVS): CVS Health Corporation Announces Cash Tender Offers for Certain Outstanding Notes Stock Update (NYSE:CVS): CVS Health Research Institute Study Shows that Home Infusion Care Improves Patient Outcomes and Quality of Life While Reducing Overall Costs Stock Update (NYSE:CVS): CVS Health Research Institute Study Shows 11.4 Percentage Point Improvement in Medication Adherence Among Patients in Specialty Connect™ Pilot